Jaguar Health, Inc. (NASDAQ: JAGX) has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value. This review aligns with the anticipated completion of clinical work supporting the filing of a New Drug Application (NDA) for its crofelemer-based prescription drug candidate for rare intestinal failure diseases. The Board of Directors is considering options that may include mergers, reverse mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions involving biotech or non-biotech companies. The company emphasized that there is no assurance this exploration will result in a completed transaction.

Lisa Conte, Jaguar's founder, president, and CEO, stated that the company remains committed to its development program for crofelemer. She believes identifying a suitable strategic alternative will support the goal of maximizing the value of the intestinal failure development program for all stakeholders, including patients, the healthcare community, and shareholders.

The strategic review coincides with clinical progress for crofelemer. In an ongoing investigator-initiated proof-of-concept trial for pediatric patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), the drug demonstrated a reduction of parenteral support of up to 37%. A late-breaking abstract with updates on this trial is scheduled for presentation at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Annual Meeting in June 2026.

Market Opportunity and Indication

Patients with intestinal failure cannot absorb sufficient nutrients or fluids and often require lifelong intravenous nutritional support. While lifesaving, this support is associated with serious complications. A third-party market research report estimates the global value of the nutritional support market for MVID, an ultrarare congenital disorder with no approved therapies, is approximately $1.1 billion in 2026, rising to approximately $1.5 billion in 2033.

Jaguar Health, Inc. develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal disease states. Its family companies, Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., focus on the development and commercialization of novel crofelemer powder for oral solution. Magdalena Biosciences, a joint venture with Filament Health Corp., focuses on developing novel prescription medicines derived from plants for mental health indications.

Magdalena Biosciences, a US-based joint venture formed by Jaguar Health and Canada-based Filament Health Corp, announced that a novel extract derived from leaves of the coca plant prevented weight gain in mice submitted to a high-fat diet without reducing food intake or increasing physical activity. The prescription drug candidate is intended for post-GLP-1 weight loss management and will be developed under the U.S. Food and Drug Administration's Botanical Guidance. The findings address the significant unmet need for safe, long-term weight management solutions due to the rebound effect often observed after stopping GLP-1 medications.

The 20-day preclinical study supports the thesis that the coca leaf extract may serve as a weight maintenance therapy following the cessation of GLP-1 therapy. It is common for people to regain weight after stopping GLP-1 medications because these drugs help reduce appetite and increase feelings of fullness while they are being taken. When treatment is discontinued, these effects diminish, and the body's mechanisms that regulate hunger and body weight may promote weight gain. Steven King, PhD, Jaguar's Chief Sustainable Supply and Ethnobotanical Research Officer and a founding Advisor to Magdalena, noted that a coca extract-based prescription drug developed under the FDA's Botanical Guidance is likely to have a low abuse potential.

Study Details

The coca leaf used in the research was provided by Empresa Nacional de La Coca (ENACO), a Peruvian state company. ENACO holds an Internationally Recognized Certificate of Compliance (IRCC) in compliance with the Nagoya Protocol requirements of Peru. Indigenous peoples in the Andean region have utilized coca for centuries to manage hunger and fatigue.

Magdalena Biosciences was formed in 2023 to develop novel, natural prescription medicines derived from plants for mental health and central nervous system indications. One Small Planet, founded by Will Peterffy, has committed funding of US$1,000,000 to the joint venture. The collaboration aims to develop pharmaceutical-grade, standardized drug candidates for weight gain prevention and mental health disorders.